Following the FDA's Fast Track designation, Elisigen has successfully completed dosing for the first cohort in its Phase 1/2a trial. This progress underscores the company's efficient execution of its clinical strategy in the global regulatory landscape.
Read Original Article (English)
*Note: This link will redirect you to the original source in English.